Cat. No. 2275
Alternative Name: NSC 231634
Chemical Name: 4,5,6,7-Tetrabromobenzotriazole
Biological ActivityA cell-permeable, selective inhibitor of casein kinase-2 (CK2) (IC50 = 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively). Exhibits modest discrimination between CK2 subunits, with Ki values ranging from 80 nM to 210 nM. Acts in an ATP/GTP-competitive manner and displays one to two orders of magnitude selectivity over a panel of 33 protein kinases.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Sarno et al (2001) Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett. 496 44. PMID: 11343704.
Pagano et al (2004) Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J.Med.Chem. 47 6239. PMID: 15566294.
Zien et al (2005) Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2. Biochim.Biophys.Acta. 1754 271. PMID: 16203192.
If you know of a relevant citation for this product please let us know.
Keywords: TBB, supplier, Selective, cell-permeable, CK2, inhibitors, Casein, Kinase, 2, Kinases, NSC231634
Find multiple products by catalog number
New Products in this Area
Potent protein kinase D (PKD) inhibitorHarmine
Potent and selective Dyrk1A inhibitorAZ 628
Potent Raf kinase inhibitorCHIR 99021 trihydrochloride
Hydrochloride salt of CHIR 99021 (Cat. No. 4423); selective GSK-3 inhibitorYZ9
PFKFB3 inhibitor; inhibits cell growthKU 0060648
Dual DNA-PK and PI 3-K inhibitorKB SRC 4
Potent and selective c-Src inhibitorProINDY
Dyrk1A/B inhibitor; prodrug of INDY (Cat. No. 4997)INDY
Dyrk1A/B inhibitorAZD 6482
Potent and selective PI 3-Kβ inhibitorAS 1892802
Potent ROCK inhibitor; orally bioavailableSC 79
Akt activatorSNS 314 mesylate
Potent pan-Aurora kinase inhibitorPD 180970
p210bcr/abl kinase inhibitor; also inhibits c-Src and KITPD 334581
MEK1 inhibitorSB 747651A dihydrochloride
Potent MSK1 inhibitor; also inhibits other AGC group kinases
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.